Pfizer beats Mylan in case over cardiovascular drug Norvasc

Pfizer prevailed over Mylan in theNorvasc litigation. Mylan acknowledged infringing on the patent, but claimed the patent was unenforceable. Mylan also contended the patent contained the incorrect formula for the drug and is therefore not valid. On Feb. 27, Judge Terrence F. McVerry of the Western District of Pennsylvania ruled that the patent covering amlodipine besylate is valid and enforceable and that a competing Mylan product would infringe upon it.